A detailed history of Cormorant Asset Management, LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,250,000 shares of ACLX stock, worth $111 Million. This represents 7.31% of its overall portfolio holdings.

Number of Shares
1,250,000
Previous 1,525,000 18.03%
Holding current value
$111 Million
Previous $84.2 Million 24.03%
% of portfolio
7.31%
Previous 6.48%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$50.91 - $86.61 $14 Million - $23.8 Million
-275,000 Reduced 18.03%
1,250,000 $104 Million
Q2 2024

Aug 14, 2024

SELL
$49.74 - $66.98 $12.7 Million - $17.1 Million
-255,000 Reduced 14.33%
1,525,000 $84.2 Million
Q1 2024

May 15, 2024

BUY
$51.85 - $73.49 $4.15 Million - $5.88 Million
80,000 Added 4.71%
1,780,000 $124 Million
Q4 2023

Feb 14, 2024

SELL
$31.75 - $57.99 $14.3 Million - $26.1 Million
-450,000 Reduced 20.93%
1,700,000 $94.4 Million
Q3 2023

Nov 14, 2023

BUY
$31.51 - $37.4 $4.73 Million - $5.61 Million
150,000 Added 7.5%
2,150,000 $77.1 Million
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $11 Million - $18.8 Million
400,000 Added 25.0%
2,000,000 $63.2 Million
Q1 2023

May 15, 2023

SELL
$26.92 - $33.94 $12.8 Million - $16.1 Million
-475,000 Reduced 22.89%
1,600,000 $49.3 Million
Q4 2022

Feb 14, 2023

SELL
$17.18 - $33.0 $16.7 Million - $32.1 Million
-974,173 Reduced 31.95%
2,075,000 $64.3 Million
Q3 2022

Nov 14, 2022

BUY
$16.67 - $22.04 $25.4 Million - $33.6 Million
1,524,173 Added 99.95%
3,049,173 $57.2 Million
Q2 2022

Aug 15, 2022

BUY
$7.21 - $24.43 $11 Million - $37.3 Million
1,525,000 New
1,525,000 $27.6 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.88B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.